73,519 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Marshall Wace LLP

Marshall Wace LLP bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,519 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,967,000. Marshall Wace LLP owned 0.13% of Supernus Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of SUPN. Congress Wealth Management LLC DE boosted its holdings in Supernus Pharmaceuticals by 37.8% during the 1st quarter. Congress Wealth Management LLC DE now owns 177,801 shares of the specialty pharmaceutical company’s stock valued at $6,065,000 after acquiring an additional 48,750 shares during the period. Sei Investments Co. grew its holdings in shares of Supernus Pharmaceuticals by 24.4% in the first quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock worth $11,276,000 after purchasing an additional 64,752 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Supernus Pharmaceuticals by 205.2% in the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after buying an additional 65,880 shares during the period. Schroder Investment Management Group bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $15,685,000. Finally, Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock valued at $179,854,000 after buying an additional 142,551 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Piper Sandler lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $41.00 to $36.00 in a research report on Wednesday, September 11th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $32.02 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $35.44. The company has a 50-day moving average of $32.40 and a 200 day moving average of $30.39. The firm has a market cap of $1.76 billion, a PE ratio of -110.41 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.39 by ($0.03). The business had revenue of $168.30 million during the quarter, compared to analysts’ expectations of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. Supernus Pharmaceuticals’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) EPS. Sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.